Corindus Vascular Robotics (NYSEAMERICAN:CVRS) was the recipient of a large decline in short interest during the month of March. As of March 29th, there was short interest totalling 13,438,496 shares, a decline of 5.2% from the March 15th total of 14,173,793 shares. Based on an average daily volume of 1,408,712 shares, the short-interest ratio is presently 9.5 days. Approximately 15.9% of the shares of the stock are sold short.
Several brokerages recently issued reports on CVRS. Zacks Investment Research downgraded Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a research report on Monday, January 29th. Cowen set a $2.00 price objective on Corindus Vascular Robotics and gave the stock a “buy” rating in a research report on Thursday, March 15th. Three research analysts have rated the stock with a sell rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $2.00.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Schwab Charles Investment Management Inc. grew its stake in shares of Corindus Vascular Robotics by 34.2% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 383,800 shares of the medical equipment provider’s stock valued at $584,000 after buying an additional 97,900 shares during the period. Essex Investment Management Co. LLC grew its stake in shares of Corindus Vascular Robotics by 55.2% during the 4th quarter. Essex Investment Management Co. LLC now owns 1,238,664 shares of the medical equipment provider’s stock valued at $1,251,000 after buying an additional 440,601 shares during the period. Millennium Management LLC purchased a new stake in shares of Corindus Vascular Robotics during the 4th quarter valued at $2,189,000. Deutsche Bank AG grew its stake in shares of Corindus Vascular Robotics by 91.6% during the 4th quarter. Deutsche Bank AG now owns 250,179 shares of the medical equipment provider’s stock valued at $251,000 after buying an additional 119,611 shares during the period. Finally, BlackRock Inc. grew its stake in shares of Corindus Vascular Robotics by 4.6% during the 4th quarter. BlackRock Inc. now owns 4,384,539 shares of the medical equipment provider’s stock valued at $4,428,000 after buying an additional 191,134 shares during the period.
Shares of CVRS opened at $1.34 on Friday. Corindus Vascular Robotics has a fifty-two week low of $0.66 and a fifty-two week high of $2.25.
Corindus Vascular Robotics (NYSEAMERICAN:CVRS) last issued its quarterly earnings results on Wednesday, March 14th. The medical equipment provider reported ($0.04) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). The company had revenue of $4.19 million during the quarter, compared to the consensus estimate of $3.90 million. Corindus Vascular Robotics had a negative return on equity of 110.93% and a negative net margin of 323.84%.
COPYRIGHT VIOLATION NOTICE: “Corindus Vascular Robotics (CVRS) Short Interest Down 5.2% in March” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/04/13/corindus-vascular-robotics-cvrs-short-interest-down-5-2-in-march.html.
About Corindus Vascular Robotics
Corindus Vascular Robotics, Inc designs, manufactures, and sells robotic-assisted precision vascular systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for radial, coronary, and peripheral procedures.
Receive News & Ratings for Corindus Vascular Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics and related companies with MarketBeat.com's FREE daily email newsletter.